Individuals Who Stopped Taking the Weight Loss Drug Tirzepatide Regained Almost Half the Weight They Misplaced

This content material initially appeared on On a regular basis Well being. Republished with permission.

By Becky Upham

After dropping greater than 20 % of their physique weight in eight months, individuals who stopped taking the burden loss drug Zepbound (tirzepatide) regained about half the burden inside a yr, based on a brand new research revealed at the moment in JAMA.

Individuals who continued to take the medicine misplaced an extra 5 % of their authentic physique weight, for a complete common weight lack of 25 % over the 88-week research.

Tirzepatide was first authorized by the U.S. Meals and Drug Administration (FDA) in Could 2022 beneath the identify Mounjaro, to enhance blood sugar management in adults with kind 2 diabetes — but it surely additionally confirmed spectacular weight reduction outcomes.

In November, the FDA authorized tirzepatide beneath the brand new identify Zepbound, for weight reduction in people with a physique mass index (BMI) of 30 or increased, and for these with a BMI of 27 or better who additionally had well being circumstances reminiscent of excessive ldl cholesterol or hypertension.

Tirzepatide Could Be a Lifelong Drug

Should you cease the medicine, you regain the burden — there’s no query that may occur, says coauthor Louis Aronne, MD, a professor of metabolic analysis and director of the Middle for Weight Administration and Metabolic Medical Analysis at Weill Cornell Drugs in New York Metropolis. “However that shouldn’t be stunning. Weight problems is a power illness that wants power therapy for the profit to be fully maintained,” he says.

The findings right here spotlight that to keep up weight reduction, individuals ought to proceed on tirzepatide long-term, says Fatima Cody Stanford, MD, MPH, an affiliate professor of medication at Harvard Medical College and weight problems drugs specialist at Massachusetts Common Hospital, each in Boston. Dr. Stanford, who can be a medical reviewer for On a regular basis Well being, was not concerned within the research.

“As famous with different GLP-1 brokers, weight achieve occurs when sufferers are taken off the agent. These brokers act on pathways of the mind that regulate weight and meals consumption, and when these sufferers are now not receiving therapy, they now not have these mind pathways to control weight, and so they regain it,” she says.

Individuals Who Stopped Taking Zepbound Had been Nonetheless 22 Kilos Lighter on Common After 1 12 months

The aim of this research was to search out out if the spectacular preliminary weight reduction after the primary eight months would proceed past the interval of energetic therapy. A complete of 670 eligible members had been randomly assigned to both proceed taking Zepbound for an extra yr (52 weeks) or to change to a placebo.

All through the trial, all members obtained life-style counseling from a professional healthcare skilled to assist them stick with a wholesome 500 energy per day deficit food regimen and not less than 150 minutes of bodily exercise per week.

Those that continued to take Zepbound misplaced an extra 5.5 % of their weight (on prime of the 20.9 % they already misplaced), whereas those that went on placebo regained about half the burden they misplaced over the course of the yr — that means they had been nonetheless down practically 10 % in contrast with their authentic weight.

In different phrases, on the finish of 88 weeks, those that continued taking tirzepetide had misplaced on common 60 kilos, and those that went on the placebo maintained a 22-pound weight reduction.

That quantity of weight reduction continues to be superb, says Aronne. “I feel many individuals suppose that everybody will instantly regain weight; that was not the case. Of the sufferers who switched to placebo, 16.6 % had been capable of keep 80 % or extra of the burden that they had misplaced,” he says.

The consequences of intensive behavioral remedy on the upkeep of weight discount weren’t evaluated, which may make a distinction in stopping weight regain after coming off the drug, the authors acknowledged.

Treating Weight problems Can Additionally Enhance Hypertension, Coronary heart Illness, and Diabetes

Weight problems is a number one driver of many illnesses, together with hypertension, coronary heart illness, diabetes, and fatty liver illness, says Aronne. “Should you had been to deal with any of those circumstances, you wouldn’t be treating any of the others, however with weight problems therapy, you may deal with all of them, and get enchancment in high quality of life measures, particularly bodily functioning,” he says.

Contributors taking Zepbound had vital enhancements in BMI, ldl cholesterol and triglyceride ranges, blood sugar, and blood stress. Some, however not all, of these advances had been misplaced within the placebo group.

“The metabolic advantages tended to revert again in the direction of baseline, however some, like insulin, triglycerides, and enhancements in high quality of life, had been nonetheless considerably higher. None had been worse than when the trial began,” says Aronne.

Once more, that is to be anticipated, since weight reduction produced all these advantages — and when there’s not as a lot weight reduction, there’s not as a lot profit, he says.

As soon as Individuals Cease Taking GLP-1s, They Will Regularly Regain Misplaced Weight

If the trial had continued to observe the individuals on placebo after a yr, each Dr. Aronne and Stanford agree that these people would ultimately regain most, if not the entire weight they misplaced.

“Would it not take one other yr? We’re unsure. In the event that they restarted the medicine, would they return to the place the group who was handled went and with the identical profit? We don’t know that both, however primarily based on our scientific expertise with medicine, that’s what I might anticipate,” says Aronne.

Weight Biking Can Hurt Well being and Contribute to Weight problems

“Weight biking causes hurt to your well being and it contributes to weight problems,” says Stanford.

Consistently dropping and gaining weight — known as weight biking or yo-yo weight-reduction plan — results in antagonistic well being outcomes, based on the Endocrine Society. Analysis has additionally linked weight biking with danger of early loss of life.

Extra Analysis Is Wanted to Discover Lengthy-Time period Dangers of Medicines

These findings recommend that individuals might have to remain on Zepbound long-term to keep up weight reduction and the related well being advantages, says Aronne.

Additional research shall be wanted to evaluate the long-term dangers and advantages related to these medication, particularly contemplating the potential for his or her lifelong use, the authors wrote.

This research is a vital step in persevering with to construct the case for the continued insurance coverage protection of GLP-1 medicines, so that individuals can keep weight reduction advantages, says Suki Singh, MD, a household drugs and weight problems drugs doctor and system medical director for weight administration and weight problems drugs at Henry Ford Well being in Detroit.

However then again, extra analysis is required to know if taking these medication indefinitely is secure, she factors out. “It’s nonetheless unknown if there are long-term issues or unwanted side effects related to these medicines, or what their affect goes to be on the intestine, or [if] there’s an elevated danger of C-cell tumors,” she says.

In rats, tirzepatide precipitated thyroid C-cell tumors but it surely isn’t but identified if the drug poses any danger for the rise of C-cell tumors in people.

“Till we now have extra knowledge out there, it’s laborious to say if these medicines are the long-term reply to treating weight problems,” says Dr. Singh.

On a regular basis Well being follows strict sourcing pointers to make sure the accuracy of its content material, outlined in our editorial coverage. We use solely reliable sources, together with peer-reviewed research, board-certified medical specialists, sufferers with lived expertise, and knowledge from prime establishments.

  1. Aronne LJ, et al. Continued Therapy With Tirzepatide for Upkeep of Weight Discount in Adults With Weight problems. JAMA. December 11, 2023.
  2. Jastreboff AM et al. Tirzepatide As soon as Weekly for the Therapy of Weight problems. The New England Journal of Drugs. July 21, 2022.
  3. FDA Approves New Medicine for Power Weight Administration. U.S. Meals and Drug Administration.
  4. FDA Approves Novel, Twin-Focused Therapy for Type 2 Diabetes. U.S. Meals and Drug Administration. Could 13, 2022.
  5. Weight Biking Is Related With a Increased Danger of Demise. Endocrine Society. November 29, 2018.
  6. Oh TJ et al. Physique-Weight Fluctuation and Incident Diabetes Mellitus, Cardiovascular Illness, and Mortality: A 16-12 months Potential Cohort Examine. The Journal of Medical Endocrinology and Metabolism. November 29, 2018.

Latest Recipes

More Recipes Like This